News - CNS Diseases

Filter

Current filters:

CNS Diseases

Popular Filters

NICE asks Biogen Idec for more information on Tecfidera

NICE asks Biogen Idec for more information on Tecfidera

21-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) is calling on US biotech firm Biogen…

Biogen IdecBiotechnologyCNS DiseasesRegulationTecfideraUK

Prana reports successful Phase II results in Huntington disease trial

18-02-2014

Australia-based Prana Biotechnology has announced positive results of its Reach2HD Phase II clinical…

AustraliaBiotechnologyCNS DiseasesNeurologicalPrana BiotechnologyResearch

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

Forest Laboratories announces new appointments to its executive team

16-12-2013

New York-based pharmaceutical company Forest Laboratories (NYSE: FRX) has announced new appointments…

Anti-viralsBoardroomCardio-vascularCNS DiseasesForest LaboratoriesGastro-intestinalsPharmaceuticalRespiratory and PulmonaryUSA

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

Collaboration agreement between French firms Vect-Horus and AAA

20-11-2013

French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

Sanofi’s Lemtrada gets support from FDA advisory panel

Sanofi’s Lemtrada gets support from FDA advisory panel

14-11-2013

French drug major Sanofi (Euronext: SAN) has received support from a US Food and Drug Administration…

CNS DiseasesEuropeGenzymeLemtradaPharmaceuticalRegulationSanofi

Novartis MS drug Gilenya leads to reduction in brain volume drug

Novartis MS drug Gilenya leads to reduction in brain volume drug

04-10-2013

Novartis has revealed new data indicating that continued treatment with Gilenya led to a reduction in…

CNS DiseasesEuropeGilenyaNovartisPharmaceuticalResearch

Inovio reveals success in DNA plasmid technology

Inovio reveals success in DNA plasmid technology

25-09-2013

US drug developer Inovio Pharmaceuticals has demonstrated the success of its new DNA plasmid technology…

Anti-Arthritics/RheumaticsBiotechnologyCNS DiseasesInovio PharmaceuticalsNorth AmericaOncologyResearch

Back to top